A Phase 4 interventional study of 0 ppm F and 250 ppm F as MFP in Caries, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-19.
Sponsored by Procter and Gamble · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the fluoride dose response of different dentifrice fluoride concentrations - 0, 250, 1100 and 2800 ppm fluoride as sodium monofluorophosphate (MFP) and a fifth leg of 1100 ppm Stannous Fluoride (SnF2) using an in situ caries model.
Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP
0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP
0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP
0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)
Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP
1100 ppm SnF2 toothpaste only
Drug: 1100 ppm SnF2
Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Each subject will be assigned to this treatment during the fifth period for this crossover study.
Enamel Fluoride Uptake (EFU)
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
Time frame: Evaluations will occur after 21 days of product use
Enamel Fluoride Uptake (EFU)
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
Time frame: Evaluations will occur after 7 days of product use
Percent Surface Microhardness (SMH)
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
Time frame: Evaluations will occur after 7 days of product use
Enamel Fluoride Uptake (EFU)
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
Time frame: Evaluations will occur after 14 days of product use
Percent Surface Microhardness (SMH)
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
Time frame: Evaluations will occur after 14 days of product use
Percent Surface Microhardness (SMH)
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
Time frame: Evaluations will occur after 21 days of product use
| Milestone | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 |
|---|---|---|---|---|
| Started | 3 | 4 | 4 | 4 |
| Completed | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 1 |
| Milestone | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 |
|---|---|---|---|---|
| Started | 3 | 4 | 4 | 3 |
| Completed | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 |
|---|---|---|---|---|
| Started | 3 | 4 | 4 | 3 |
| Completed | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 |
|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 |
| Completed | 3 | 3 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 |
|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 |
| Completed | 2 | 3 | 4 | 3 |
| Not completed | 1 | 0 | 0 | 0 |
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
| μg F/cm^2 | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Enamel Fluoride Uptake (EFU) | 2.28 ± 0.709 | 4.51 ± 0.709 | 8.78 ± 0.736 | 14.05 ± 0.709 | 7.43 ± 0.423 |
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
| μg F/cm^2 | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Enamel Fluoride Uptake (EFU) | 3.13 ± 0.881 | 5.20 ± 0.882 | 8.20 ± 0.916 | 13.52 ± 0.850 | 9.11 ± 0.670 |
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
| Percent SMH Recovery | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Percent Surface Microhardness (SMH) | 15.92 ± 3.259 | 22.50 ± 3.264 | 22.42 ± 3.360 | 35.61 ± 3.160 | 26.32 ± 4.605 |
The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.
| μg F/cm^2 | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Enamel Fluoride Uptake (EFU) | 3.86 ± 1.141 | 7.23 ± 1.141 | 11.53 ± 1.185 | 18.92 ± 1.141 | 12.65 ± 1.215 |
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
| Percent SMH Recovery | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Percent Surface Microhardness (SMH) | 10.49 ± 4.258 | 18.62 ± 4.258 | 24.76 ± 4.369 | 38.08 ± 4.258 | 28.28 ± 4.562 |
The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.
| Percent SMH Recovery | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Percent Surface Microhardness (SMH) | 4.76 ± 4.921 | 11.14 ± 4.921 | 17.51 ± 5.068 | 33.38 ± 4.921 | 17.91 ± 3.108 |
Collected over Each participant was monitored throughout the whole study, up to 4 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0 Ppm F (Placebo, Negative Control) | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| 250 Ppm F as MFP (Dose-response Control) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| 1100 Ppm F as MFP (Reference) | 0/13 (0%) | 0/13 (0%) | 2/13 (15.4%) |
| 2800 Ppm F as MFP (Dose-response Control) | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| 1100 Ppm SnF2 | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | 0 Ppm F (Placebo, Negative Control) | 250 Ppm F as MFP (Dose-response Control) | 1100 Ppm F as MFP (Reference) | 2800 Ppm F as MFP (Dose-response Control) | 1100 Ppm SnF2 |
|---|---|---|---|---|---|
| Tooth BrokenGastrointestinal disorders | 0/14 | 0/14 | 1/13 | 0/14 | 0/13 |
| Neck PainInjury, poisoning and procedural complications | 0/14 | 0/14 | 1/13 | 0/14 | 0/13 |
| CoughingRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 | 0/13 | 0/14 | 0/13 |
| Irritation MouthGastrointestinal disorders | 1/14 | 1/14 | 0/13 | 0/14 | 0/13 |
| Edentulous Ridge ErythmeaGastrointestinal disorders | 1/14 | 0/14 | 0/13 | 0/14 | 0/13 |
| VaginitisReproductive system and breast disorders | 0/14 | 1/14 | 0/13 | 0/14 | 0/13 |
| Renal Kidney TumorRenal and urinary disorders | 0/14 | 0/14 | 0/13 | 1/14 | 0/13 |
| Irritation GumGastrointestinal disorders | 0/14 | 0/14 | 0/13 | 1/14 | 0/13 |
| Irritation TongueGastrointestinal disorders | 0/14 | 0/14 | 0/13 | 1/14 | 0/13 |
| Lung CancerRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/13 | 1/14 | 0/13 |
| Age, Continuous(years) | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 | Total |
|---|---|---|---|---|---|
| Mean | 69.7 ± 8.33 | 72.5 ± 4.51 | 69.7 ± 9.50 | 76.3 ± 9.32 | 72.2 ± 7.75 |
| Sex: Female, Male(Participants) | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 4 | 2 | 9 |
| Male | 2 | 2 | 0 | 2 | 6 |
| Race (NIH/OMB)(Participants) | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 3 | 4 | 9 |
| White | 2 | 2 | 1 | 0 | 5 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race and Ethnicity Not Collected(Participants) | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(participants) | 0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2 | 250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF2 | 1100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF2 | 2800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2 | Total |
|---|---|---|---|---|---|
| United States | 3 | 4 | 4 | 4 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Jul 2021, 4 months.
Results were first posted in Jul 2022, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.